Tralostam can inhibit the synthesis of corticosteroids β- Dehydrogenase, which reduces the synthesis of cortisol and aldosterone, is clinically used to treat Cushing's syndrome (hypercortisolemia) and primary Chemicalbook aldosteronism. However, the efficacy of treating Cushing's syndrome (hypercortisolemia) is not as good as that of metoprolone. This product also has a significant effect on reducing blood testosterone levels, which may be related to inhibiting its synthesis.
Mechanism of action
Breast cancer is a hormone dependent tumor, and estrogen is the main driver of the growth of this cancer cell. Therefore, one of the modern main therapies for breast cancer is to target estrogen, blocking the role of estrogen by inhibiting the production of estrogen or by blocking the estrogen receptor at its action site. Previously, it was believed that estrogen receptors were only a single receptor, but recent research has identified that they at least exist α and β Two subtypes. Among them, estrogen binding α- Estrogen receptors can stimulate cell growth, but are associated with β- Estrogen receptor binding is downregulated α- Female Chemicalbook hormone receptors slow down cell proliferation rate. Research has revealed that tralostam can not only reduce estrogen production, but also regulate the binding of estrogen to different subtypes of estrogen receptors, while also showing α- Estrogen receptor inhibitors and β- The dual effects of estrogen receptor agonists ultimately block and alter the negative effects of estrogen on cancer cells. Tralostam's unique mode of action not only distinguishes it from other existing anti estrogen drugs, but also is the pharmacological basis for its highly effective treatment of breast cancer that fails to be treated by other anti estrogen therapies or is resistant to drugs.
Treatment of advanced breast cancer
Breast cancer is the most common tumor type in women. At present, for postmenopausal patients with hormone receptor positive or unknown type of breast cancer, clinical consensus recommends that anti estrogen drugs be the first choice for treatment, and the role of this therapy in delaying disease progression and improving survival time has long been affirmed and confirmed by a large number of studies. The new drug, Tralostam (trade name Modrenal), developed by biotech company BioEnvision, has been launched for the treatment of postmenopausal women with hormonal Chemicalbook selective cancer that has spread beyond the breast. The drug is used in two ways to slow down disease progression. For hormone sensitive breast cancer, estrogen promotes cancer cell growth by acting on two receptors, the estrogen receptor а Like cancer accelerators, estrogen receptors β It is the brake. Modrenol enhances the effect of estrogen on estrogen receptors β The adsorption of estrogen receptors weakens а The role of. At the same time, it also acts on another site AP1 on the cell DNA to reduce cell proliferation.